GenSci and Osteotech settle bone implant litigation
This article was originally published in Clinica
Executive Summary
GenSci Regeneration Sciences, the Toronto, Canada-based company with orthobiologics facilities in Irvine, California, and its Eaton, New Jersey rival, Osteotech, have signed a settlement agreement that brings to an end their long-running dispute over osteogenic bone implants. GenSci, which is currently in Chapter 11 bankruptcy protection, will pay Osteotech $7.5m, $1m of which will be payable after it emerges from Chapter 11, and the remainder in 20 quarterly instalments.